Moreover, combination therapy of anti‐PD‐1 and CCL2‐CCR2 axis inhibition may be a novel and promising therapeutic approach for improving anti‐tumour efficacy, which provides new directions for cancer immunotherapy and warrants further study in clinical trials. The gene discussed is CCL2; the disease is cancer.